| Product Code: ETC8531558 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Overview |
3.1 Netherlands Country Macro Economic Indicators |
3.2 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, 2021 & 2031F |
3.3 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Industry Life Cycle |
3.4 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Porter's Five Forces |
3.5 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Gene Type, 2021 & 2031F |
3.7 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about alpha-1 antitrypsin deficiency (AATD) among healthcare providers and patients |
4.2.2 Growing prevalence of AATD in the Netherlands |
4.2.3 Advancements in research and development of augmentation therapies for AATD |
4.3 Market Restraints |
4.3.1 High cost associated with augmentation therapy for AATD |
4.3.2 Limited reimbursement options for AATD augmentation therapy |
4.3.3 Regulatory challenges and stringent approval processes for new therapies in the Netherlands |
5 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Trends |
6 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Types |
6.1 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Prolastin, 2021- 2031F |
6.1.4 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Zemaira/Respreeza, 2021- 2031F |
6.1.5 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Glassia, 2021- 2031F |
6.1.6 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Aralast NP, 2021- 2031F |
6.1.7 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Gene Type |
6.2.1 Overview and Analysis |
6.2.2 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiZZ, 2021- 2031F |
6.2.3 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiMS, 2021- 2031F |
6.2.4 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Type PiMZ, 2021- 2031F |
6.2.5 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Lung Disease, 2021- 2031F |
6.3.3 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Liver Disease, 2021- 2031F |
6.3.4 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Population Type, 2021- 2031F |
6.3.5 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Adults and Pediatric, 2021- 2031F |
6.4 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.4 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Home Healthcare, 2021- 2031F |
6.4.5 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.5 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenues & Volume, By Others, 2021- 2031F |
7 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Import-Export Trade Statistics |
7.1 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Export to Major Countries |
7.2 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Imports from Major Countries |
8 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Key Performance Indicators |
8.1 Patient adherence rate to AATD augmentation therapy |
8.2 Number of healthcare providers trained in the diagnosis and management of AATD |
8.3 Research funding allocated to AATD in the Netherlands |
9 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Opportunity Assessment |
9.1 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Gene Type, 2021 & 2031F |
9.3 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market - Competitive Landscape |
10.1 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue Share, By Companies, 2024 |
10.2 Netherlands Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here